CapsoVision (CV) Cash from Investing Activities (2024 - 2025)

CapsoVision (CV) reported Cash from Investing Activities of -$8000.0 for Q4 2025, up 33.33% sequentially from -$12000.0 in Q3 2025.

CapsoVision (CV) Cash from Investing Activities (2024 - 2025) Analysis & Trends

CapsoVision (CV) has 2 years of Cash from Investing Activities data on file, last reported at -$8000.0 in Q4 2025.

For the quarter ending Q4 2025, Cash from Investing Activities changed N/A year-over-year to -$8000.0; the trailing twelve-month figure through Dec 2025 stood at -$24000.0 (changed N/A YoY), and the FY2025 full-year result was -$90000.0, up 41.18% from the prior year.
Cash from Investing Activities grew to -$8000.0 in Q4 2025, from -$12000.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of -$4000.0 in Q3 2024 to a low of -$12000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Abbott Laboratories	184.15 Bn	176.85 Bn	6.27 Bn	-20.32 Bn
2	Stryker	128.85 Bn	125.98 Bn	3.81 Bn	-185.00 Mn
3	Medtronic	108.75 Bn	99.53 Bn	6.41 Bn	-917.00 Mn
4	Boston Scientific	68.66 Bn	67.21 Bn	3.61 Bn	-591.00 Mn
5	Edwards Lifesciences	48.24 Bn	44.57 Bn	1.29 Bn	-92.80 Mn
6	Dexcom	28.42 Bn	27.30 Bn	750.30 Mn	-298.50 Mn
7	GE HealthCare Technologies	28.32 Bn	26.03 Bn	1.98 Bn	-2.50 Bn
8	Smith & Nephew	26.93 Bn	26.35 Bn	-	-
9	Koninklijke Philips	25.31 Bn	22.18 Bn	2.07 Bn	-475.32 Mn
10	CapsoVision	164.28 Mn	154.16 Mn	1.95 Mn	-8,000.00

Download Data